Organon & Co. · NYSE:OGN
Organon & — Shareholder Meeting (June 2025)
16 slides from Organon &'s shareholder meeting presentation, Jun 10, 2025
Slide 1: 2025 Annual Meeting of Shareholders Agenda
ORGANON & CO. Tuesday, June 10, 2025 2025 Annual Meeting of Shareholders 9:00 AM Eastern Daylight Time PART I • Preliminary Procedural Remarks and Opening of the Polls • Opening Remarks and Introduction of Directors and Attendees PART II Agenda • Call to Order • Statement Regarding the Notice of Mee
Slide 2: Organon Board of Directors
[Organon] Proprietary Organon Board of Directors Carrie S. Cox Kevin Ali Robert Essner Alan Ezekowitz, Helene Gayle, Chairman, Organon; Chief Executive Officer, Former Chairman, Former CEO and former Organon & Co. President and Chief M.D., Ph.D. M.D., MPH Chairman of Humacyte and Executive Officer,
Slide 3: Executive officers
[Organon] Proprietary Executive officers Kevin Ali Juan Camilo Arjona Aaron Falcione Daniel Karp Joseph Chief Executive Officer Ferreira, M.D. Chief Human Head of Corporate Morrissey Resources Officer Development Head of Research & Head of Manufacturing Development and Chief & Supply Medical Officer
Slide 4: 2025 Annual Meeting of Shareholders Agenda
ORGANON & CO. Tuesday, June 10, 2025 2025 Annual Meeting of Shareholders 9:00 AM Eastern Daylight Time PART I • Preliminary Procedural Remarks and Opening of the Polls • Opening Remarks and Introduction of Directors and Attendees PART II Agenda • Call to Order • Statement Regarding the Notice of Mee
Slide 5: 2025 Organon Annual Meeting of Shareholders
2025 Organon Annual Meeting of Shareholders June 10, 2025
Slide 6: Cautionary Note Regarding Forward-Looking Statements
ORGANON & CO. Tuesday, June 10, 2025 2025 Annual Meeting of Shareholders Disclaimer Statement – Cautionary Note Regarding Forward-Looking Statements 9:00 AM Eastern Daylight Time Except for historical information, this presentation includes “forward-looking statements” within the meaning of the safe
Slide 7: Non-GAAP Information
ORGANON & CO. 2025 Annual Meeting of Shareholders Tuesday, June 10, 2025 9:00 AM Eastern Daylight Time Non-GAAP Information This presentation contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are correspondingly not excluded or included
Slide 8: 2025 Organon Annual Meeting of Shareholders
2025 Organon Annual Meeting of Shareholders June 10, 2025
Slide 9: Continued our momentum in 2024
Continued our momentum in 2024 3 The number of years each of our Reinforced our focus on driving strategic franchises – Women’s Health, Biosimilars, growth with the acquisition of Vtama, the only and Established Brands – have delivered non-steroidal topical approved for mild, constant currency reven
Slide 10: FY 2024 highlights
FY 2024 highlights Third consecutive year of constant currency revenue growth Each franchise contributed to $6.4B $4.11 growth Total Revenue Adjusted Diluted EPS 2 Women’s 5% growth ex-FX up 3%, ex-FX 1 Health Biosimilars 12% growth ex-FX $1.96B Non-GAAP Adjusted Established Brands 2% growth ex-FX E
Slide 11: Our strategic roadmap
Our strategic roadmap Accelerate growth & profitability 2026 - beyond Preparing for lean growth 2024-2026 • Accelerate revenue and Adjusted Establish Organon EBITDA growth CAGRs 2021-2024 • Maintain revenue growth CAGR and hold Adjusted EBITDA • Accelerate delivery of strategic margin floor through
Slide 12: Organon - Here for her health
“= ORGANON Here for her health
Slide 13: Questions & Answers
Questions & Answers ORGANON Here for her health
Slide 14: Thank you
Thank you ORGANON Here for her health
Slide 15: Appendix A
Appendix A ORGANON Here for her health
Slide 16: Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA
Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA Year Ended Unaudited, $ in millions December 31, 2024 GAAP Reported Net Income 864 Depreciation(1) 126 Amortization 145 Interest expense 520 Income tax expense (57) EBITDA (Non-GAAP) 1,598 Restructuring costs 31 Spin-related costs(2) 121